Vision, Low
Conditions
Brief summary
The eSight Quality of Life and Efficacy Study (eQUEST) is a prospective cohort study intended to demonstrate the functional vision and Quality of Life (QoL) improvement provided by eSight Eyewear to persons with significant visual impairment resulting from various eye conditions. The multi-site study will evaluate the efficacy of the eSight device for various Activities of Daily Living (ADLs) across a broad range of subject ages and disease types.
Detailed description
Subjects will receive an initial benchmark assessment to determine their visual function. This includes standard clinical tests for acuity and contrast performance. Subjects will then receive a demonstration of the device. If the demonstration shows favourable results (improved functional visual performance for some rudimentary tasks such as reading), and the subject consents to the study, the subject will return to the site a week later to receive their personalized device (lens prescriptions incorporated into the unit), and more comprehensive training on its operation. They will then use the unit in their home/work/school environment over a period of three months. At the start of the study, after a period of one month, and at the end of the three month period, the subject will visit the clinical setting for administration of various specified ADL tasks, and the Veterans Affairs (VA) Low Vision (LV) Visual Function Questionnaire (VFQ) 48-question VA LV VFQ-48 survey. The intent of this repetition is to understand how ADL proficiency and VFQ-48 QoL assessment changes over time, as the subject becomes more accustomed to the device.
Interventions
DEVICEeSight Eyewear
primary intervention
Sponsors
Johns Hopkins University
Université de Montréal
University Health Network, Toronto
Vitreous and Retina Consultants PA
University of Michigan
Bascom Palmer Eye Institute
eSight Corporation
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
13 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
1. Male or female subjects between the ages of 13-75. 2. Subjects have been diagnosed with one of the following low vision conditions: Diabetic Retinopathy, Stargardt's Disease, Age Related Macular Degeneration, Leber's Disease, Retinopathy of Prematurity, Cone Rod Dystrophy, or Ocular Albinism . 3. Subject must have distance Best Corrected Visual Acuity (BCVA) measured with Early Treatment Diabetic Retinopathy Study (ETDRS) chart of between 20:60 and 20:400 in the better eye. 4. Subject must have a functional field of view of at least 20 degrees (bilateral or monocular). Field need not be centrally located. 5. If the subject is employed, they must be prepared to use eSight Eyewear in their workplace environment, have informed their employer of their involvement in the study, and received permission from their employer to bring eSight Eyewear into the workplace. If the subject is self-employed, they must be prepared to use eSight Eyewear in their workplace environment. Similarly if the subject is a student, they must be prepared to use eSight Eyewear in their educational environment. 6. Subject must be, in the opinion of the examiner, highly motivated, alert, articulate, mentally competent and able to understand and comply with the requirements of the study (defined herein). 7. Subject must provide informed consent. Subjects under the age of majority must have a legal guardian present during the informed consent process, who must sign the Informed Consent form on their behalf. 8. Subject must agree to use eSight Eyewear only under conditions that will not jeopardize the safety of either the user or the device.
Exclusion criteria
1. Subject must not be currently undergoing any medical or surgical procedures resulting in unstable vision. 2. Subjects for whom their vision, for whatever reason, can be considered unstable. 3. Subjects who have undergone cataract, refractive, or other surgical procedures related to vision in the six month period prior to the study. 4. Subjects who have undergone any eyesight-related injections (e.g. anti-VEGF) in the two month period prior to the study because of active bleeds in the retina. Ongoing anti-VEGF treatments are permitted if subject is in a Treat and Extend or pro re nata (PRN) disease management, and macula is dry. 5. Subjects unable or unwilling to adhere to the examination schedules as they are described in the study protocol. This may also include Subjects already enrolled who, for whatever reason become unable or unwilling to continue the study. This may also include subjects for whom the travel time to/from the study site is unacceptable. 6. Subjects who self report a history of alcoholism, drug abuse or psychosis, Subjects who exhibit clinical evidence of depression, poor motivation, emotional or intellectual problems, or any other conditions which would likely limit validity of consent or appropriate responses to participate in the study or who are deemed unsuitable psychologically or physiologically for study participation by the investigator. 7. Subjects who may have a conflict of interest with eSight Corp, which could reasonably influence their participation in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Quality of Life Improvement After Three Months of Device Use | Baseline and after three months of device use. | The study seeks to quantify, after a period of usage of the device of three months, improvement in subjects' Quality of Life using the validated tool, Veterans Affairs (VA) Low Vision (LV) Visual Functioning Questionnaire (VFQ) - 48 Questions (VA LV VFQ-48). Quality of Life is measured in Logits. Individual scores ranged from -5 to +10 (a higher number is a better score). Overall improvement was 0.84 Logits. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Improvement in Visual Acuity | Baseline and after three months of device use. | The study seeks to quantify, after a period of usage of the device of three months, improvement in visual acuity using standard optometric charts (e.g. 20/400 to 20/160, etc.). We measured LogMAR acuity on a standard ETDRS chart. Results show an average greater than seven-line improvement (-0.76 LogMAR). |
| Improvement in Visual Contrast Performance in Log Units. | Baseline and after three months of device use. | The study seeks to quantify, after a period of usage of the device of three months, improvement in contrast performance using a standard optometric Mars Contrast Chart. Outcome is measured in Log Units ranging from 0.04 to 1.92 in decrements of 0.04 log units, a higher score indicating better contrast performance. The scale of the Mars Contrast Chart is interpreted as follows: 0.0 - 0.5 Log Units: Profound Loss 0.5 - 1.0 Log Units: Severe Loss 1.0 - 1.5 Log Units: Moderate Loss 1.5 - 1.75 Log Units: Normal Vision (\>60yrs) \>1.75 Log Units: Normal Vision (\<60yrs) |
Countries
Canada, United States
Participant flow
Recruitment details
51 participants selected from the patient population at six low vision rehabilitation clinics, in the period Dec 16, 2015 through September 19, 2016.
Pre-assignment details
The study had only one arm.
Participants by arm
| Arm | Count |
|---|---|
| eSight Eyewear Main arm
eSight Eyewear: primary intervention | 51 |
| Total | 51 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Incomplete data | 6 |
| Overall Study | Lack of Efficacy | 7 |
| Overall Study | Lost to Follow-up | 2 |
| Overall Study | Protocol Violation | 5 |
| Overall Study | Withdrawal by Subject | 3 |
Baseline characteristics
| Characteristic | eSight Eyewear | — |
|---|---|---|
| Age, Categorical <=18 years | 3 Participants | — |
| Age, Categorical >=65 years | 9 Participants | — |
| Age, Categorical Between 18 and 65 years | 39 Participants | — |
| Age, Continuous | 48 years STANDARD_DEVIATION 17.2 | — |
| Race and Ethnicity Not Collected | — | — Participants |
| Sex: Female, Male Female | 21 Participants | — |
| Sex: Female, Male Male | 30 Participants | — |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 74 |
| other Total, other adverse events | 0 / 74 |
| serious Total, serious adverse events | 0 / 74 |
Outcome results
Primary
Quality of Life Improvement After Three Months of Device Use
The study seeks to quantify, after a period of usage of the device of three months, improvement in subjects' Quality of Life using the validated tool, Veterans Affairs (VA) Low Vision (LV) Visual Functioning Questionnaire (VFQ) - 48 Questions (VA LV VFQ-48). Quality of Life is measured in Logits. Individual scores ranged from -5 to +10 (a higher number is a better score). Overall improvement was 0.84 Logits.
Time frame: Baseline and after three months of device use.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| eSight Eyewear | Quality of Life Improvement After Three Months of Device Use | 0.84 Logits | Standard Deviation 1.265 |
Secondary
Improvement in Visual Acuity
The study seeks to quantify, after a period of usage of the device of three months, improvement in visual acuity using standard optometric charts (e.g. 20/400 to 20/160, etc.). We measured LogMAR acuity on a standard ETDRS chart. Results show an average greater than seven-line improvement (-0.76 LogMAR).
Time frame: Baseline and after three months of device use.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| eSight Eyewear | Improvement in Visual Acuity | -0.76 LogMAR | Standard Deviation 0.3 |
Secondary
Improvement in Visual Contrast Performance in Log Units.
The study seeks to quantify, after a period of usage of the device of three months, improvement in contrast performance using a standard optometric Mars Contrast Chart. Outcome is measured in Log Units ranging from 0.04 to 1.92 in decrements of 0.04 log units, a higher score indicating better contrast performance. The scale of the Mars Contrast Chart is interpreted as follows: 0.0 - 0.5 Log Units: Profound Loss 0.5 - 1.0 Log Units: Severe Loss 1.0 - 1.5 Log Units: Moderate Loss 1.5 - 1.75 Log Units: Normal Vision (\>60yrs) \>1.75 Log Units: Normal Vision (\<60yrs)
Time frame: Baseline and after three months of device use.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| eSight Eyewear | Improvement in Visual Contrast Performance in Log Units. | 0.53 Log Units | Standard Deviation 0.55 |